指南与共识妇产影像PETCT

HIV状态不影响局部晚期宫颈癌患者的PET-CT表现或放疗治疗建议

HIV status does not have an impact on positron emission tomography-computed tomography (PET-CT) findings or radiotherapy treatment recommendations in patients with locally advanced cervical cancer.
指南 / 共识 · Int J Gynecol Cancer · 2019-08-13

该研究纳入南非开普敦癌症中心2015年1月至2018年12月连续278例FIGO IIB–IIIB期宫颈癌患者,其中HIV阴性192例(69.1%)、HIV阳性86例(30.9%),分析PET-CT表现及后续治疗。结果显示淋巴结受累和远处转移与HIV状态无关,PET-CT分期升级及治疗意图改变在两组间无显著差异。

要点

  • HIV阳性与HIV阴性局部晚期宫颈癌患者的PET-CT淋巴结受累及远处转移无差异。
  • PET-CT后分期升级率HIV阴性83.9% vs HIV阳性87.2%,无显著差异(p=0.47)。
  • PET-CT后治疗意图改变率HIV阳性53.6% vs HIV阴性42.9%,无显著差异(p=0.11)。

核心结论

  • HIV阳性与HIV阴性局部晚期宫颈癌患者在淋巴结受累或隐匿性转移方面无差异,PET-CT未导致或证明两组间治疗差异。

研究设计与样本

  • 研究为队列研究,纳入南非开普敦癌症中心2015年1月至2018年12月连续278例FIGO IIB–IIIB期宫颈癌患者,其中HIV阴性192例(69.1%)、HIV阳性86例(30.9%)。
  • 患者需经胸部X线或腹部超声分期无远处病变征象、多学科团队认为适合根治性放化疗且肾功能正常方行PET-CT;HIV阳性者需连续抗病毒治疗超过3个月且CD4细胞计数高于150 cells/μL。
  • 排除小细胞癌和神经内分泌癌病例;采用18F-FDG PET-CT扫描,记录人口学、PET-CT表现及后续治疗。

关键影像表现/征象

  • 超过80%的患者有盆腔淋巴结受累,超过40%的患者有髂总动脉和/或腹主动脉旁淋巴结摄取。
  • 54例(19.4%)至少有一个远处转移部位。

临床应用与阅片要点

  • HIV阳性患者行PET-CT前需满足连续抗病毒治疗超过3个月且CD4细胞计数高于150 cells/μL的条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: Positron emission tomography-computed tomography (PET-CT) imaging is commonly used to identify nodal involvement in locally advanced cervical carcinoma, but its appropriateness for that purpose among HIV-positive patients has rarely been studied. We analyzed PET-CT findings and subsequent treatment prescribed in patients with locally advanced cervical carcinoma in Cape Town, South Africa.

METHODS: We identified a cohort of consecutive cervical carcinoma patients International Federation of Gynecology and Obstetrics (FIGO) stage IIB to IIIB at our cancer center who underwent a planning 18-fluorodeoxyglucose (18FDG) PET-CT scan from January 2015 through December 2018. Demographics, PET-CT findings, and subsequent treatment prescribed were recorded. Patients were selected for PET-CT only if they had no signs of distant disease on staging chest X-ray or abdominal ultrasound; were deemed suitable for radical chemoradiation by the multi-disciplinary team; and had normal renal function. HIV-positive patients ideally had to have been established on continuous antiviral therapy for more than 3 months and to have a CD4 cell count above 150 cells/μL. Small cell and neuroendocrine carcinoma cases were excluded from the study. Differences in demographic and clinical measures between HIV-positive and HIV-negative patients were evaluated by means of t-tests for continuous variables and χ2 tests for categorical variables.

RESULTS: Over a 4 year period, 278 patients-192 HIV-negative (69.1%) and 86 HIV-positive (30.9%)-met the inclusion criteria. HIV-positive patients had a median CD4 count of 475 cells/µL (IQR 307-612 cells/µL). More than 80% of patients had pelvic nodal involvement, and more than 40% had uptake in common iliac and/or para-aortic nodes. Nodal involvement was not associated with HIV status. Fifty-four patients (19.4%) had at least one site of distant metastatic disease. Overall, 235 patients (84.5%) were upstaged following PET-CT staging scan. Upstaging was not associated with HIV status (HIV-negative 83.9% vs HIV-positive 87.2%; p=0.47). Ten patients who did not return for radiotherapy were excluded from the analysis. Following their PET-CT scan, treatment intent changed for 124 patients (46.3%): 53.6% of HIV-positive patients and 42.9% of HIV-negative patients (p=0.11).

CONCLUSION: We found no differences between HIV-positive or HIV-negative patients in nodal involvement or occult metastases, and PET-CT imaging did not lead to, or justify, treatment differences between the two groups. Future studies will evaluate survival and correlation of upstaging with outcome.

来源:Int J Gynecol Cancer,查看原文。版权归原作者所有。

引用

  1. Simonds H, Botha MH, Ellmann A, et al. HIV status does not have an impact on positron emission tomography-computed tomography (PET-CT) findings or radiotherapy treatment recommendations in patients with locally advanced cervical cancer. Int J Gynecol Cancer. 2019. PMID: 31413068. doi:10.1136/ijgc-2019-000641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。